Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: Main Inclusion Criteria:~1. Is male or female and ≥18 and \<75 years old at time of informed consent.~2. Has a HbA1c of ≥7.5% and ≤10.5% based on central laboratory results from Visit 1, with individual need for therapy escalation.~3. Currently treated with a stable maximum tolarated dose (MTD) (≥1500 mg/day) of metformin therapy for at least 8 weeks prior to Enrolment visit.~4. Has a BMI of ≤45 kg/m2 at Enrolment visit.~5. Has a C-peptide laboratory value of ≥1.0 ng/mL (0.33 nmol/L; 333.3 pmol/L) based on central laboratory results from Visit 1.~Main, Exclusion Criteria:~1. Clinically diagnosed with Type I diabetes, known diagnosis of maturity onset diabetes of the young (MODY), or secondary diabetes mellitus or known presence of glutamate decarboxylase 65 (GAD65) antibodies.~2. Patients who, in the judgment of the Investigator, may be at risk for dehydration or volume depletion that may affect the patient's safety and/or the interpretation of efficacy or safety data.~3. Clinically significant cardiovascular disease or procedure within 3 months prior to Enrolment or expected to require coronary revascularization procedure during the course of the study.~4. Concomitant treatment with loop diuretics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin+metformin (Type: ACTIVE_COMPARATOR): Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
- Dapagliflozin+saxagliptin+metformin (Type: ACTIVE_COMPARATOR): Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
- Glimepiride+metformin (Type: ACTIVE_COMPARATOR): Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).